
|Videos|December 15, 2015
- Breast Cancer (Issue 2)
- Volume 1
- Issue 2
Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to Treatment
Author(s)William Sikov, MD
William Sikov, MD, associate director of Clinical Research, Program in Women
Advertisement
William Sikov, MD, associate director of Clinical Research, Program in Women’s Oncology, Women and Infants Hospital of Rhode Island, on the phase II CALGB 40603 trial, which tested if standard neoadjuvant chemotherapy plus carboplatin and/or bevacizumab would result in a pathologic complete response in patients with stage II/III triple-negative breast cancer.
Articles in this issue
about 10 years ago
Dr. Carey Anders on Treating Brain Metastases in Breast Cancerabout 10 years ago
Dr. Matthew J. Ellis on Neoadjuvant Palbociclib in Primary Breast Cancerabout 10 years ago
Avelumab Shows Efficacy in PD-L1-Positive Metastatic Breast CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5










































